SentreHeart said today it won CE Mark approval in the European Union for its Lariat surgical left atrial appendage suture delivery device used for soft tissue closure. The device is commonly used for the ligation of the LAA as an adjunctive treatment to ablation in patients with persistent atrial fibrillation, the Redwood City, Calif.-based company […]
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
St. Jude Medical’s $3B Thoratec buyout set to close today
Thoratec (NSDQ:THOR) said its shareholders approved St. Jude Medical‘s (NYSE:STJ) $3.4 billion buyout offer yesterday, setting the stage for the deal to close today. In August, U.S. anti-trust regulators cleared the deal, in which Pleasanton, Calif.-based Thoratec’s stockowners are due to receive $63.50 in cash for each THOR share. Little Canada, Minn.-based St. Jude took out a 5-year, $2.6 […]
Boston Scientific ups stake in stealthy MValve and its TMVI docking tech
Boston Scientific (NYSE:BSX) said today that it boosted its stake in stealthy Israeli medical device company MValve, which is developing “docking” technology for transcatheter mitral valve implants. Marlborough, Mass.-based Boston Scientific put $15 million into MValve last year in a deal that included a $200 million buyout option. MValve, which is based in San Diego and […]
EBR Systems wins CE Mark for wireless pacer
EBR Systems said Monday it won CE Mark approval in the European Union for its WiSE wireless endocardial cardiac resynchronization therapy device. The EBR device uses a subcutaneous generator to wirelessly deliver ultrasound energy to a “pellet” implanted on the inside of the heart, in the right ventricle, which it uses to synchronize the left […]
Cardiac Insight closes Cardea buyout
Cardiac Insight said last week it closed its purchase of cardiovascular diagnostic developer Cardea Associates for an undisclosed amount. Cardea’s flagship product is the CardeaScreen, a handheld 12-lead electrocardiogram device and software that Cardiac Insight says “provides a major breakthrough” in improving quality and reliability of ECGs to identify issues associated with sudden cardiac arrest […]
Boston Scientific slips $200m patent spat with stent pioneer Jang
Boston Scientific (NYSE:BSX) last week escaped a long-running royalties dispute with coronary stent pioneer Dr. David Jang that could have cost it $200 million. Judge Virginia Phillips of the U.S. District Court for Central California found Sept. 29 that Jang’s claims covered previous patents, triggering the ensnarement defense barring a patentee from asserting a scope of equivalency that would encompass, […]
TransMedics wins FDA panel date for organ preservation device
The FDA plans to convene an advisory panel to review the pre-market approval bid for the organ preservation device made by TransMedics. The FDA’s Gastroenterology & Urology Devices panel is slated to meet Nov. 18 to discuss Andover, Mass.-based TransMedics’ PMA bid for its Organ Care System, which is designed to perfuse a donor heart with warm, oxygenated blood and monitor its status until […]
Silk Road launches Enroute transcarotid stent
Silk Road Medical said today it launched its Enroute Transcarotid stent system in the U.S., and that the stent was used in its 1st commercial commercial case. The Enroute stent is indicated for use in patients at high surgical risk in conjunction with the company’s transcarotid Neuroprotection system, the Sunnyvale, Calif.-based company said. The stent […]
Corindus wins FDA nod for radial access stenting with CorPath
Corindus Vascular Robotics (OTC:CVRS) said today it won FDA 510(k) clearance for its robotic-assisted CorPath System for use during percutaneous coronary interventions stenting procedures performed via radial access. The approval was based on results from a 30-patient clinical trial of the device that demonstrated a 100% device and clinical success rate, the Waltham, Mass.-based company said. “Radial […]
TAVI: Study prompts FDA notice on blood clot risk
A small study published yesterday in the New England Journal of Medicine, finding reduced leaflet mobility in some replacement heart valves, prompted the FDA to caution doctors about the risk of blood clots on the devices. The finding is notable because it involves both transcatheter aortic heart implants and surgical aortic valve implants, which have been in […]
Medtronic closes TMVI developer Twelve Inc. buy
Medtronic (NYSE:MDT) said today it closed its $458 million purchase of transcatheter mitral valve replacement device developer Twelve Inc. Medtronic will pay $408 million for the developer and another $50 million pegged to CE Mark approval in the European Union for the Twelve TMVR device, the company said. “This acquisition supports Medtronic’s therapy innovation strategy, as […]